Abstract
In a phase I trial of endoxifen, a metabolite of tamoxifen, multiple patients with estrogen receptor-positive breast cancer that was resistant to treatment with aromatase inhibitors had partial responses or long-lasting stable disease.
MeSH terms
-
Antineoplastic Agents, Hormonal / administration & dosage
-
Antineoplastic Agents, Hormonal / adverse effects
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Female
-
Humans
-
Selective Estrogen Receptor Modulators / administration & dosage
-
Selective Estrogen Receptor Modulators / adverse effects
-
Selective Estrogen Receptor Modulators / therapeutic use*
-
Tamoxifen / administration & dosage
-
Tamoxifen / adverse effects
-
Tamoxifen / analogs & derivatives*
-
Tamoxifen / therapeutic use
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Selective Estrogen Receptor Modulators
-
Tamoxifen
-
4-hydroxy-N-desmethyltamoxifen